Fulcrum Therapeutics, Inc. (FULC) — Analyst outlook / Analyst consensus target is. Based on 16 analyst ratings, the consensus is bullish — 11 Buy, 4 Hold, 1 Sell.
The consensus price target is $20.57 (low: $10.00, high: $25.00), representing an upside of 160.4% from the current price $7.90.
Analysts estimate Earnings Per Share (EPS) of $-0.15 and revenue of $0.08B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.17 vs est $-0.15 (missed -14.6%). 2025: actual $-1.18 vs est $-1.16 (missed -1.4%). Analyst accuracy: 93%.
FULC Stock — 12-Month Price Forecast
$20.57
▲ +160.38% Upside
Average Price Target
Based on 16 Wall Street analysts offering 12-month price targets for Fulcrum Therapeutics, Inc., the average price target is $20.57, with a high forecast of $25.00, and a low forecast of $10.00.
The average price target represents a +160.38% change from the last price of $7.90.
Highest Price Target
$25.00
Average Price Target
$20.57
Lowest Price Target
$10.00
FULC Analyst Ratings
Buy
Based on 16 analysts giving stock ratings to Fulcrum Therapeutics, Inc. in the past 3 months
EPS Estimates — FULC
93%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.17
vs Est –$0.15
▼ 12.7% off
2025
Actual –$1.18
vs Est –$1.16
▼ 1.4% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — FULC
99%
Analyst Accuracy
Accurate
1 year compared
Actual vs Estimate
2024
Actual $0.080B
vs Est $0.080B
▼ 0.6% off
Revenue Trend
Revenue has declined over the period shown. Analysts expect stable revenue going forward.
